“This approval is the answer to a question on which we’ve been relentlessly focused: How do we continue to improve an already effective therapy for daily use?” said Kimberly Moran, PhD, SVP & Head, U.S. Rare Diseases at UCB. “As the first treatment to be approved as a once-daily autoinjector option for adults living with gMG in the U.S., ZILBRYSQ now provides the same therapy via another administration option. At UCB, we are committed to science and make it our point to continually help improve how people experience it.”
